Uterine Cancer Therapeutics & Diagnostics
Global Uterine Cancer Therapeutics and Diagnostics Market to Reach $24.3 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Uterine Cancer Therapeutics and Diagnostics estimated at US$18.4 Billion in the year 2020, is projected to reach a revised size of US$24.3 Billion by 2027, growing at aCAGR of 4.1% over the period 2020-2027. Endometrial Carcinomas, one of the segments analyzed in the report, is projected to record 5% CAGR and reach US$16 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Uterine Sarcomas segment is readjusted to a revised 2.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $5.1 Billion, While China is Forecast to Grow at 7.6% CAGR
The Uterine Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$5.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$5 Billion by the year 2027 trailing a CAGR of 7.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.5% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.
Select Competitors (Total 46 Featured) -
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook